The consensus price target for Coya Therapeutics, Inc. (NASDAQ:COYA) has remained stable at $17, with a slightly higher target of $18 from analyst Raghuram Selvaraju.Recent 10.7% increase in share price reflects investor optimism, despite the lack of sustained improvement in earnings estimate revisions.Future clinical trial results or regulatory approvals are key to the company's stock performance and future price targets.Coya Therapeutics, Inc. (NASDAQ:COYA) is a clinical-stage biotechnology company dedica ...